Amid pricing spat with U.K. government, Vertex declines to submit data on new CF drug to NICE
admin 10th August 2018 Uncategorised 0After failing to reach a pricing deal on Orkambi for nearly three years, Vertex has declined to submit data on a new CF drug to England’s NICE for appraisal.
More: Amid pricing spat with U.K. government, Vertex declines to submit data on new CF drug to NICE
Source: fierce